NCT06838208 Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
| NCT ID | NCT06838208 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Anhui Provincial Cancer Hospital |
| Condition | Extensive-stage Small Cell Lung Cancer (ES-SCLC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 56 participants in total. It began in 2025-02-25 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Eligibility Criteria
Inclusion Criteria: 1. Age≥18 years old, male or female, signed Informed Consent Form (ICF); 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 3. Histologically or cytologically confirmed ES-SCLC; 4. No prior systemic treatment for ES-SCLC; 5. At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation; 6. Adequate hematologic and end organ function; Exclusion Criteria: 1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis; 2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody; 3. Was administered a live vaccine ≤ 4 weeks before treatment; 4. Active autoimmune diseases or history of autoimmune diseases that may relapse; 5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment; 6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases; 7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection; 8. Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06838208 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Extensive-stage Small Cell Lung Cancer (ES-SCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06838208 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06838208 currently recruiting?
Yes, NCT06838208 is actively recruiting participants. Contact the research team at yuanshuanghu@sina.com for enrollment information.
Where is the NCT06838208 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT06838208 clinical trial?
NCT06838208 is sponsored by Anhui Provincial Cancer Hospital. The trial plans to enroll 56 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.